As we have noted several times, the National Cancer Institute (NCI) is vital in the fight against cancer. And one of its key initiatives is the PREVENT Cancer Preclinical Drug Development Program.
From the NCI: PREVENT Cancer Preclinical Drug Development Program
According to the NCI:
PREVENT is a peer-reviewed program designed to support development of the best ideas in cancer prevention using NCI contract resources. The program offers pipeline that focuses on unmet needs in prevention not adequately addressed by the private sector. Read more about Concept Application Peer-Review Process.
PREVENT will allocate NCI contract resources and expertise to generate data and materials. Used by applicants of successfully approved concepts to further advance their novel cancer preventive agents (singly or in combination). Or biomarkers toward IND filing and proof-of-principle clinical testing. Read more about Technology Transfer Considerations for the PREVENT Studies.
PREVENT provides flexible entry points. At any point in development, from discovery to clinical, agents and biomarkers trial will get consideration for support. Although not a grant program, PREVENT utilizes NCI-funded contractors to carry out the necessary next steps of research for applicants. All results or products go back to applicants. And they support further development by the applicants or in partnership with DCP.
For more insights on the PREVENT process, review the infographic.
